{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:09:38Z","timestamp":1790827778425,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670148"],"award-info":[{"award-number":["81670148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key R&D Program of Zhejiang Province","award":["2019C03016"],"award-info":[{"award-number":["2019C03016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00277-020-04106-2","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T17:03:08Z","timestamp":1591722188000},"page":"2679-2687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia"],"prefix":"10.1007","volume":"99","author":[{"given":"Fei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huarui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-5574","authenticated-orcid":false,"given":"Yanmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"issue":"1","key":"4106_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1046\/j.1365-2141.2001.02468.x","volume":"112","author":"A Dominietto","year":"2001","unstructured":"Dominietto A, Raiola AM, van Lint MT, Lamparelli T, Gualandi F, Berisso G, Bregante S, Frassoni F, Casarino L, Verdiani S, Bacigalupo A (2001) Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 112(1):219\u2013227. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02468.x","journal-title":"Br J Haematol"},{"issue":"9","key":"4106_CR2","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.bbmt.2016.06.003","volume":"22","author":"Y Akahoshi","year":"2016","unstructured":"Akahoshi Y, Kanda J, Gomyo A, Hayakawa J, Komiya Y, Harada N, Kameda K, Ugai T, Wada H, Ishihara Y, Kawamura K, Sakamoto K, Sato M, Terasako-Saito K, Kimura SI, Kikuchi M, Nakasone H, Kako S, Kanda Y (2016) Risk factors and impact of secondary failure of platelet recovery after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 22(9):1678\u20131683. https:\/\/doi.org\/10.1016\/j.bbmt.2016.06.003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"4106_CR3","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2008-10-167643","volume":"113","author":"EC Vamvakas","year":"2009","unstructured":"Vamvakas EC, Blajchman MA (2009) Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 113(15):3406\u20133417. https:\/\/doi.org\/10.1182\/blood-2008-10-167643","journal-title":"Blood"},{"issue":"9763","key":"4106_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","volume":"377","author":"G Cheng","year":"2011","unstructured":"Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 377(9763):393\u2013402. https:\/\/doi.org\/10.1016\/S0140-6736(10)60959-2","journal-title":"Lancet"},{"issue":"23","key":"4106_CR5","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","volume":"130","author":"RSM Wong","year":"2017","unstructured":"Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB (2017) Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 130(23):2527\u20132536. https:\/\/doi.org\/10.1182\/blood-2017-04-748707","journal-title":"Blood"},{"issue":"1","key":"4106_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1200931","volume":"367","author":"MJ Olnes","year":"2012","unstructured":"Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE (2012) Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 367(1):11\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1200931","journal-title":"N Engl J Med"},{"issue":"12","key":"4106_CR7","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","volume":"123","author":"R Desmond","year":"2014","unstructured":"Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE (2014) Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 123(12):1818\u20131825. https:\/\/doi.org\/10.1182\/blood-2013-10-534743","journal-title":"Blood"},{"issue":"10","key":"4106_CR8","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00277-015-2440-x","volume":"94","author":"YQ Sun","year":"2015","unstructured":"Sun YQ, He GL, Chang YJ, Xu LP, Zhang XH, Han W, Chen H, Chen YH, Wang Y, Wang FR, Wang JZ, Liu KY, Huang XJ (2015) The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Ann Hematol 94(10):1699\u20131705. https:\/\/doi.org\/10.1007\/s00277-015-2440-x","journal-title":"Ann Hematol"},{"issue":"9","key":"4106_CR9","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.bbmt.2019.05.036","volume":"25","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Gao F, Shi J, Luo Y, Tan Y, Lai X, Yu J, Huang H (2019) Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 25(9):1898\u20131907. https:\/\/doi.org\/10.1016\/j.bbmt.2019.05.036","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4106_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s003300000528","volume":"11","author":"F Robertson","year":"2001","unstructured":"Robertson F, Leander P, Ekberg O (2001) Radiology of the spleen. Eur Radiol 11(1):80\u201395. https:\/\/doi.org\/10.1007\/s003300000528","journal-title":"Eur Radiol"},{"issue":"17","key":"4106_CR11","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","volume":"124","author":"Y Luo","year":"2014","unstructured":"Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Zhu Y, Ye X, Yu X, Cai Z, Lin M, Huang H (2014) T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 124(17):2735\u20132743. https:\/\/doi.org\/10.1182\/blood-2014-04-571570","journal-title":"Blood"},{"issue":"6","key":"4106_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/MAJ.0000000000000186","volume":"347","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Luo Y, Shi J, Cai Z, Huang H (2014) Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia. Am J Med Sci 347(6):439\u2013445. https:\/\/doi.org\/10.1097\/MAJ.0000000000000186","journal-title":"Am J Med Sci"},{"issue":"2","key":"4106_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","volume":"27","author":"CL Erickson-Miller","year":"2009","unstructured":"Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, Duffy KJ, Jenkins JM (2009) Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 27(2):424\u2013430. https:\/\/doi.org\/10.1634\/stemcells.2008-0366","journal-title":"Stem Cells"},{"issue":"19","key":"4106_CR14","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1182\/blood-2018-11-884486","volume":"133","author":"LJ Alvarado","year":"2019","unstructured":"Alvarado LJ, Huntsman HD, Cheng H, Townsley DM, Winkler T, Feng X, Dunbar CE, Young NS, Larochelle A (2019) Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-gamma. Blood 133(19):2043\u20132055. https:\/\/doi.org\/10.1182\/blood-2018-11-884486","journal-title":"Blood"},{"key":"4106_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2019.03.002","volume":"73","author":"KL Guenther","year":"2019","unstructured":"Guenther KL, Cheruku PS, Cash A, Smith RH, Alvarado LJ, Burkett S, Townsley DM, Winkler T, Larochelle A (2019) Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells. Exp Hematol 73:1\u20136.e6. https:\/\/doi.org\/10.1016\/j.exphem.2019.03.002","journal-title":"Exp Hematol"},{"issue":"22","key":"4106_CR16","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","volume":"116","author":"W Bao","year":"2010","unstructured":"Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, Yazdanbakhsh K (2010) Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 116(22):4639\u20134645. https:\/\/doi.org\/10.1182\/blood-2010-04-281717","journal-title":"Blood"},{"issue":"6","key":"4106_CR17","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1182\/blood-2016-01-690727","volume":"128","author":"XG Liu","year":"2016","unstructured":"Liu XG, Liu S, Feng Q, Liu XN, Li GS, Sheng Z, Chen P, Liu Y, Wei Y, Dong XY, Qin P, Gao C, Ma C, Zhang L, Hou M, Peng J (2016) Thrombopoietin receptor agonists shift the balance of Fcgamma receptors toward inhibitory receptor IIb on monocytes in ITP. Blood 128(6):852\u2013861. https:\/\/doi.org\/10.1182\/blood-2016-01-690727","journal-title":"Blood"},{"issue":"3","key":"4106_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/09537104.2019.1624709","volume":"31","author":"R Kapur","year":"2020","unstructured":"Kapur R, Aslam R, Speck ER, Rebetz JM, Semple JW (2020) Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP). Platelets 31(3):399\u2013402. https:\/\/doi.org\/10.1080\/09537104.2019.1624709","journal-title":"Platelets"},{"issue":"17","key":"4106_CR19","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2016-10-740241","volume":"130","author":"E Vlachodimitropoulou","year":"2017","unstructured":"Vlachodimitropoulou E, Chen YL, Garbowski M, Koonyosying P, Psaila B, Sola-Visner M, Cooper N, Hider R, Porter J (2017) Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood 130(17):1923\u20131933. https:\/\/doi.org\/10.1182\/blood-2016-10-740241","journal-title":"Blood"},{"issue":"21","key":"4106_CR20","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1182\/blood-2018-01-826784","volume":"131","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, Sun Q, Sokoll LJ, Streiff M, Cheng Z, Grasmeder S, Townsley DM, Young NS, Dunbar CE, Winkler T (2018) Eltrombopag mobilizes iron in patients with aplastic anemia. Blood 131(21):2399\u20132402. https:\/\/doi.org\/10.1182\/blood-2018-01-826784","journal-title":"Blood"},{"issue":"21","key":"4106_CR21","doi-asserted-by":"publisher","first-page":"30892","DOI":"10.18632\/oncotarget.8810","volume":"7","author":"Y Kong","year":"2016","unstructured":"Kong Y, Song Y, Hu Y, Shi MM, Wang YT, Wang Y, Zhang XH, Xu LP, Liu KY, Deng HK, Huang XJ (2016) Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants. Oncotarget 7(21):30892\u201330906. https:\/\/doi.org\/10.18632\/oncotarget.8810","journal-title":"Oncotarget"},{"issue":"2","key":"4106_CR22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1182\/blood-2011-12-399667","volume":"120","author":"M Roth","year":"2012","unstructured":"Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U (2012) Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood 120(2):386\u2013394. https:\/\/doi.org\/10.1182\/blood-2011-12-399667","journal-title":"Blood"},{"issue":"4","key":"4106_CR23","doi-asserted-by":"publisher","first-page":"e0126691","DOI":"10.1371\/journal.pone.0126691","volume":"10","author":"A Kalota","year":"2015","unstructured":"Kalota A, Selak MA, Garcia-Cid LA, Carroll M (2015) Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival. PLoS One 10(4):e0126691. https:\/\/doi.org\/10.1371\/journal.pone.0126691","journal-title":"PLoS One"},{"issue":"5","key":"4106_CR24","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.bbmt.2016.01.018","volume":"22","author":"T Tanaka","year":"2016","unstructured":"Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T (2016) Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 22(5):919\u2013924. https:\/\/doi.org\/10.1016\/j.bbmt.2016.01.018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"4106_CR25","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41409-019-0442-3","volume":"54","author":"S Marotta","year":"2019","unstructured":"Marotta S, Marano L, Ricci P, Cacace F, Frieri C, Simeone L, Trastulli F, Vitiello S, Cardano F, Pane F, Risitano AM (2019) Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplant 54(8):1346\u20131353. https:\/\/doi.org\/10.1038\/s41409-019-0442-3","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"4106_CR26","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41409-019-0435-2","volume":"54","author":"H Fu","year":"2019","unstructured":"Fu H, Zhang X, Han T, Mo X, Wang Y, Chen H, Han W, Wang J, Wang F, Yan C, Zhang Y, Sun Y, Liu K, Huang X, Xu L (2019) Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant 54(8):1310\u20131318. https:\/\/doi.org\/10.1038\/s41409-019-0435-2","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"4106_CR27","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.bbmt.2019.01.027","volume":"25","author":"C Yuan","year":"2019","unstructured":"Yuan C, Boyd AM, Nelson J, Patel RD, Varela JC, Goldstein SC, Ahmad S, Zhu X, Mori S (2019) Eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 25(7):1320\u20131324. https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.027","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"4106_CR28","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.bbmt.2019.05.023","volume":"25","author":"L Bento","year":"2019","unstructured":"Bento L, Bastida JM, Garcia-Cadenas I, Garcia-Torres E, Rivera D, Bosch-Vilaseca A, De Miguel C, Martinez-Munoz ME, Fernandez-Aviles F, Roldan E, Chinea A, Yanez L, Zudaire T, Vaz CP, Espigado I, Lopez J, Valcarcel D, Duarte R, Cabrera R, Herrera C, Gonzalez-Porras JR, Gutierrez A, Solano C, Sampol A, Grupo Espanol de Trasplante H (2019) Thrombopoietin receptor agonists for severe thrombocytopenia after allogeneic stem cell transplantation: experience of the Spanish group of hematopoietic stem cell transplant. Biol Blood Marrow Transplant 25(9):1825\u20131831. https:\/\/doi.org\/10.1016\/j.bbmt.2019.05.023","journal-title":"Biol Blood Marrow Transplant"},{"key":"4106_CR29","doi-asserted-by":"publisher","unstructured":"Masetti R, Vendemini F, Quarello P, Girardi K, Prete A, Fagioli F, Pession A, Locatelli F (2020) Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children. Pediatr Blood Cancer:e28208. https:\/\/doi.org\/10.1002\/pbc.28208","DOI":"10.1002\/pbc.28208"},{"issue":"10","key":"4106_CR30","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/j.bbmt.2018.06.021","volume":"24","author":"Y Song","year":"2018","unstructured":"Song Y, Zhao HY, Lyu ZS, Cao XN, Shi MM, Wen Q, Tang FF, Wang Y, Xu LP, Zhang XH, Huang XJ, Kong Y (2018) Dysfunctional bone marrow mesenchymal stem cells in patients with poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 24(10):1981\u20131989. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.021","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4106_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17474086.2017.1271319","volume":"10","author":"M Franchini","year":"2017","unstructured":"Franchini M, Veneri D, Lippi G (2017) Thrombocytopenia and infections. Expert Rev Hematol 10(1):99\u2013106. https:\/\/doi.org\/10.1080\/17474086.2017.1271319","journal-title":"Expert Rev Hematol"},{"key":"4106_CR32","doi-asserted-by":"publisher","unstructured":"Vardon-Bounes F, Ruiz S, Gratacap MP, Garcia C, Payrastre B, Minville V (2019) Platelets are critical key players in sepsis. Int J Mol Sci 20(14). https:\/\/doi.org\/10.3390\/ijms20143494","DOI":"10.3390\/ijms20143494"},{"issue":"7","key":"4106_CR33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.bbmt.2017.03.019","volume":"23","author":"A Ghobadi","year":"2017","unstructured":"Ghobadi A, Fiala MA, Ramsingh G, Gao F, Abboud CN, Stockerl-Goldstein K, Uy GL, Grossman BJ, Westervelt P, DiPersio JF (2017) Fresh or cryopreserved CD34(+)-selected mobilized peripheral blood stem and progenitor cells for the treatment of poor graft function after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 23(7):1072\u20131077. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4106_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/bjh.15012","volume":"180","author":"C Mainardi","year":"2018","unstructured":"Mainardi C, Ebinger M, Enkel S, Feuchtinger T, Teltschik HM, Eyrich M, Schumm M, Rabsteyn A, Schlegel P, Seitz C, Schwarze CP, Muller I, Greil J, Bader P, Schlegel PG, Martin D, Holzer U, Doring M, Handgretinger R, Lang P (2018) CD34(+) selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. Br J Haematol 180(1):90\u201399. https:\/\/doi.org\/10.1111\/bjh.15012","journal-title":"Br J Haematol"},{"issue":"9","key":"4106_CR35","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1089\/scd.2009.0029","volume":"18","author":"N Meuleman","year":"2009","unstructured":"Meuleman N, Tondreau T, Ahmad I, Kwan J, Crokaert F, Delforge A, Dorval C, Martiat P, Lewalle P, Lagneaux L, Bron D (2009) Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cells Dev 18(9):1247\u20131252. https:\/\/doi.org\/10.1089\/scd.2009.0029","journal-title":"Stem Cells Dev"},{"issue":"9","key":"4106_CR36","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3727\/096368912X661319","volume":"23","author":"X Liu","year":"2014","unstructured":"Liu X, Wu M, Peng Y, Chen X, Sun J, Huang F, Fan Z, Zhou H, Wu X, Yu G, Zhang X, Li Y, Xiao Y, Song C, Xiang AP, Liu Q (2014) Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant 23(9):1087\u20131098. https:\/\/doi.org\/10.3727\/096368912X661319","journal-title":"Cell Transplant"},{"issue":"6","key":"4106_CR37","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00277-018-3278-9","volume":"97","author":"Y Shimomura","year":"2018","unstructured":"Shimomura Y, Hara M, Katoh D, Hashimoto H, Ishikawa T (2018) Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 97(6):1049\u20131056. https:\/\/doi.org\/10.1007\/s00277-018-3278-9","journal-title":"Ann Hematol"},{"issue":"6","key":"4106_CR38","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/bmt.2012.249","volume":"48","author":"G Akpek","year":"2013","unstructured":"Akpek G, Pasquini MC, Logan B, Agovi MA, Lazarus HM, Marks DI, Bornhaeuser M, Ringden O, Maziarz RT, Gupta V, Popat U, Maharaj D, Bolwell BJ, Rizzo JD, Ballen KK, Cooke KR, McCarthy PL, Ho VT (2013) Effects of spleen status on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplant 48(6):825\u2013831. https:\/\/doi.org\/10.1038\/bmt.2012.249","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4106_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.1988.tb00861.x","volume":"41","author":"H Wadenvik","year":"1988","unstructured":"Wadenvik H, Kutti J (1988) The spleen and pooling of blood cells. Eur J Haematol 41(1):1\u20135","journal-title":"Eur J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04106-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04106-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04106-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T23:18:00Z","timestamp":1623194280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04106-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["4106"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04106-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"3 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was in compliance with the Declaration of Helsinki and was approved by the Ethics Review Committee of the First Affiliated Hospital of Zhejiang University. Informed consent was obtained from each patient in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}